<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="36724">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01783821</url>
  </required_header>
  <id_info>
    <org_study_id>12-008192</org_study_id>
    <nct_id>NCT01783821</nct_id>
  </id_info>
  <brief_title>LIPS-B: Lung Injury Prevention Study With Budesonide and Beta</brief_title>
  <acronym>LIPS-B</acronym>
  <official_title>LIPS-B: Lung Injury Prevention Study With Budesonide and Beta Agonist (Formoterol)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Arizona</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      THE STUDY WILL ANSWER WHETHER INHALED BUDESONIDE AND FORMOTEROL ARE ABLE TO ALLEVIATE OR
      PREVENT PULMONARY INJURY WHEN ADMINISTERED EARLY IN HOSPITAL COURSE TO THE PATIENTS AT RISK
      FOR DEVELOPING ARDS
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Change in oxygen saturation to fraction of inspired oxygen concentration (S/F) ratio</measure>
    <time_frame>Change in S/F ratio from baseline to day 5 after the first treatment</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Acute Respiratory Distress Syndrome (ARDS)</condition>
  <arm_group>
    <arm_group_label>budesonide and formoterol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Budesonide and formoterol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal saline, the quantity and appearance same as the intervention arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide and formoterol</intervention_name>
    <description>Patients randomized to one of two intervention arms, will receive combined standard aerosolized doses of budesonide (0.5 mg) and formoterol (20 mcg) every 12 hours, for 5 days or until hospital discharge or death, with the first dose administered as soon as possible following randomization but not later than 4 hours.</description>
    <arm_group_label>budesonide and formoterol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients (age &gt; 18);

          -  Admitted to the hospital through the emergency department (ED);

          -  High risk of developing ARDS (Lung Injury Prediction Score-LIPS greater than or equal
             to four;

          -  New chest radiograph performed on clinical grounds

        Exclusion Criteria:

          -  Inhaled corticosteroid and/or beta agonist treatment on admission or within 7 days
             prior to admission (history of asthma or COPD necessitating therapy)

          -  Chronic pulmonary disease requiring daytime oxygen supplementation therapy

          -  Systemic steroid treatment on admission or within 7 days prior to admission
             equivalent to more than 5 mg of prednisone daily

          -  Inability to obtain consent within 12 hours of hospital presentation

          -  Acute lung injury prior to randomization

          -  Receiving mechanical ventilation before current hospital admission (patient who is
             ventilator dependent)

          -  Presentation believed to be purely due to heart failure without other known risk
             factors for ARDS

          -  Allergy or other contraindication to either budesonide and/or formoterol use

          -  Expected hospital stay and/or survival &lt;48 hours or admission for comfort or hospice
             care

          -  Patient, surrogate or physician not committed to full support (exception: a patient
             will not be excluded if he/she would receive all supportive care except for attempts
             at resuscitation from cardiac arrest)

          -  Previous enrollment in this trial.

          -  Co-enrollment with LIPS-A trial is not allowed.

          -  An active enrollment in other concomitant trial will be judged on case by case basis
             by PIs of both trials.

          -  EKG and/or clinical presentation suggestive of acute coronary ischemia

          -  New onset cardiac arrhythmia

          -  Current atrial fibrillation with ventricular rate of &gt;110/minute

          -  Persistent sinus tachycardia of &gt;130/minute despite early goal directed  therapy with
             fluids, pressors, antibiotics and supplemental oxygen Pregnant patients
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emir Festic, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Arizona</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85721</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gordon Carr, MD</last_name>
      <email>gcarr@deptofmed.arizona.edu</email>
    </contact>
    <contact_backup>
      <last_name>Heidi Erickson</last_name>
      <email>herickso@email.arizona.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Gordon Carr, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosemary Vojnik</last_name>
      <email>rvojnik@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Joseph E Levitt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic in Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pamela Long, BSN</last_name>
      <phone>904-953-7719</phone>
      <email>long.pamela@mayo.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kellie Ruday, BS</last_name>
      <phone>(904) 9537766</phone>
      <email>ruday.kellie@mayo.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Emir Festic, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beth Israel Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valerie Goodspeed</last_name>
      <email>vgoodspe@bidmc.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Daniel Talmor, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 13, 2013</lastchanged_date>
  <firstreceived_date>January 31, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Emir Festic</investigator_full_name>
    <investigator_title>M.D.</investigator_title>
  </responsible_party>
  <keyword>Acute respiratory distress syndrome (ARDS)</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
    <mesh_term>Lung Injury</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Budesonide</mesh_term>
    <mesh_term>Formoterol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
